Senkyunolide I, a natural product isolated and purified from the roots of Ligusticum chuanxiong hort with anti-oxidation and anti-apoptosis properties, is traditionally used to treat migraine, can reduce the metamorphose damage of the RBC caused by ConA, alleviates the aggregation of the RBC, and protect rat brain against focal cerebral ischemia-reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3.
Senkyunolide I/洋川芎内酯I 细胞实验
Cell Line
Concentration
Treated Time
Description
References
MDCK-MDR1 cells
20, 40, 80 µg/mL
To evaluate the effect of Senkyunolide I on the transport of PF in MDCK-MDR1 cells. Results showed that Senkyunolide I significantly increased the transport of PF in the A→B direction, indicating it enhances PF transport by down-regulating P-gp expression and opening tight junctions.
Molecules. 2016 Mar 2;21(3):300.
Senkyunolide I/洋川芎内酯I 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
BALB/c mice
Anti-atherosclerosis model
Oral
132.40 mg/L
Blood samples collected after 1 hour
To study the potential therapeutic mechanisms of TSMT against atherosclerosis
Chin Med. 2022 Sep 2;17(1):103
Zebrafish
Ischemic stroke model
Co-incubation
50 μg/mL
24 hours
Senkyunolide I significantly ameliorated the behavioral abnormalities of ischemic stroke zebrafish, manifested by enhanced total swimming distance, average speed of motion, and movement time.
Drug Des Devel Ther. 2024 Sep 18;18:4183-4202
Zebra fish
PHZ-induced thrombotic model
Embryo medium
50 μg/ml
24 hours
Senkyunolide I significantly inhibited PHZ-induced thrombosis and showed synergistic antithrombotic effects when combined with cryptotanshinone.
Front Pharmacol. 2021 Jan 14;11:622787
Sprague-Dawley (SD) male rats
Middle cerebral artery occlusion (MCAO) model
Oral
75 mg/kg
Single dose
To investigate the pharmacokinetic interactions between Senkyunolide I and warfarin in MCAO rat model, results showed that Senkyunolide I significantly increased the AUC0-t and Cmax of warfarin
搜索
